Eli Lilly (LLY) was admonished by a California lawmaker for promoting a diabetes help center for patients who cannot afford their insulin while at the same time failing to lower prices or comply with a new state law that requires drug makers to disclose pricing details.
In a harshly worded letter sent on Monday, state Sen. Ed Hernandez, who sponsored the transparency law, criticized the company for touting its Diabetes Solution Center at the same time that prices for insulin, made by several companies, has risen dramatically in recent years. An analysis published two years ago found that the cost of insulin, on average, more than tripled — from $231 to $736 a year per patient — between 2002 and 2013.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
State Senator Hernandez’ view is probably oversimplistic,
but he should be congratulated as having his heart
in the right place for his constituents.